A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Progression Free Survival (PFS)

Timeframe: Up to 4 Years and 6 months

PFS is defined as the time from the date of first dose of any study treatment until the date of objective disease progression or death, whichever occurs first according to response evaluation criteria in solid tumors (RECIST) version (v) 1.1 as assessed by the investigator.

Number of Participants Reporting Dose Reductions, Interruptions, and Discontinuations

Timeframe: Up to 4 Years and 6 months

Participants with dose reductions, interruptions, and discontinuations will be reported.

Number of Participants With Venous Thromboembolic Events (VTEs)

Timeframe: Up to 4 Years and 6 months

Participants with signs and symptoms (dyspnea, tachypnea, upper- or lower-extremity swelling and discoloration) of VTE events, specifically pulmonary embolism, and deep vein thrombosis will be reported as monitored by the investigators.

Number of Participants With Dermatologic Adverse Events (AEs)

Timeframe: Up to 4 Years and 6 months

Participants with dermatologic AEs will be reported.

Number of Participants with AEs by Severity

Timeframe: Up to 4 Years and 6 months

Severity of AEs will be graded according to the national cancer institute common terminology criteria for adverse event (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1: mild, Grade 2: moderate, Grade 3: severe, Grade 4: life-threatening and Grade 5: death related to adverse event.

Overall Survival (OS)

Timeframe: Up to 4 Years and 6 months

OS is defined as the time from the date of first dose of any study treatment until the date of death due to any cause.

Overall Response Rate (ORR)

Timeframe: Up to 4 Years and 6 months

ORR is defined as the percentage of participants who achieve either a partial response (PR) or complete response (CR) as their best response both confirmed and unconfirmed, as defined using RECIST v1.1.

Clinical Benefit Rate (CBR)

Timeframe: Up to 4 Years and 6 months

CBR is defined as the percentage of participants achieving CR or PR, both confirmed and unconfirmed, or durable stable disease (SD) of a duration of at least 11 weeks as defined using RECIST v1.1.

Duration of Response (DOR)

Timeframe: Up to 4 Years and 6 months

DOR is defined as the time from the date of first documented response (PR or CR) until the date of documented progression or death, whichever occurs first, for participants who have PR or CR.

Time to Treatment Discontinuation (TTTD)

Timeframe: Up to 4 Years and 6 months

TTTD is defined as the date from the date of first dose of any study treatment until discontinuation of study treatment for any reason, including disease progression, treatment toxicity or death, based on RECIST v 1.1.

Time to Subsequent Therapy (TTST)

Timeframe: Up to 4 Years and 6 months

TTST is defined as the time from the date of first dose of any study treatment until the start date of the subsequent anticancer therapy following study treatment discontinuation or death, whichever occurs first.

Time to Symptomatic Progression (TTSP)

Timeframe: Up to 4 Years and 6 months

TTSP is defined as the time from date of first dose of any study treatment to documentation in the electronic case report form (eCRF) of any of the following (whichever occurs earlier): onset of new symptoms or symptom worsening that is considered by the investigator to be related to lung cancer and requires either a change in systemic anticancer treatment and/or clinical intervention to manage symptoms or death.